At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- daraxonrasib (drug)
- How long the study runs
- Study runs about 55 months (dates as stated)
- About the drug or intervention
- daraxonrasib — drug: oral tablets
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at a drug called daraxonrasib (RMC-6236) in people who have had surgery for pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. The surgery was done to try to cure the cancer, and there is no sign the cancer has come back or spread. The study is run by Revolution Medicines, Inc.
Who can take part
- You are at least 18 years old and have agreed (given informed consent) to take part
- You are well enough to carry out day-to-day activities (performance status of 0 or 1)
- Your pancreatic cancer (PDAC) was confirmed by looking at tissue under a microscope, and surgery to remove it was successful with no signs of the cancer returning or spreading
- You have had chemotherapy before or after surgery (or both) using more than one drug
- You finished your most recent treatment within the past 12 weeks
- Your bone marrow, liver, kidneys and blood clotting are working well enough
- Doctors have a record of whether your cancer has a change (mutation) in a gene called RAS
- You are able to swallow medicines by mouth
Who may not be able to
- You have had treatment before that directly targets RAS (such as drugs that block or break down RAS)
- You have a condition that could stop you taking or absorbing the study medicine
- You have had major surgery within 28 days before joining the study
- You cannot or do not want to attend the study visits and tests required by the study plan
What taking part involves
- • Taking a study medicine called daraxonrasib (RMC-6236) by mouth (a tablet or capsule)
- • Attending study visits and having tests and procedures as set out in the study plan
Time commitment: Not stated — ask the trial team about how long the study lasts, how often visits happen, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 500
- Started
- 2025-12-15
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for pancreatic cancer
- • Phase3 - 500 participants
- • The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with pancreatic cancer
Where?
- • Birmingham - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre
- • Glasgow - Beatson West of Scotland Cancer Centre
- • Liverpool - Clatterbridge Cancer Centre NHS Foundation Trust
- • London - The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London
- • +2 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
More detail
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy
- ✓ completed most recent treatment within the past 12 weeks
What the study is looking for
- ✓At least 18 years old and has provided agreement to take part.
- ✓activity scale (ECOG) performance status of 0 or 1.
- ✓confirmed by a biopsy PDAC with successful (R0/R1) curative intent surgical resection and no evidence of...
- ✓Must have received perioperative (before surgery, after surgery, or a combination of both) multi-agent drug treatment.
- ✓Must have completed most recent treatment within the past 12 weeks.
Who cannot take part
- ✗Prior therapy with direct RAS-treatment that targets specific changes in the cancer (eg. degraders and/or inhibitors).
- ✗Any conditions that may affect the ability to take or absorb the study treatment.
- ✗Major surgery within 28 days prior to randomization.
- ✗Patient is unable or unwilling to comply with protocol-required study visits or procedures.
See the full criteria
Where Is This Study? (6 UK sites)
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre
Birmingham B15 2TH, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow G22 0YN, United Kingdom
Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool L7 8YA, United Kingdom
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London
London SW3 6JJ, United Kingdom
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital
London W12 0HS, United Kingdom
The Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
How to Get in Touch
Revolution Medicines Study Director
Sponsor contactCONTACT